ON Helix Pitching Day 2026

Cambridge CardioMatrix presented its innovative Active Epicardial Support Device (ASD) platform at the ON Helix Pitching Day & Pre-event Clinic, held in advance of the ON Helix 2026 conference. The event brought together emerging life sciences companies, investors, industry leaders, and innovation experts, providing a valuable platform to showcase promising healthcare technologies.

Representing Cambridge CardioMatrix, CEO Marshal Ma introduced the company's pioneering closed-loop, non-blood-contact cardiac support platform, which is being developed to transform the treatment and management of advanced heart failure.

Unlike conventional mechanical circulatory support devices that require direct blood contact and are associated with risks such as thrombosis, bleeding, and infection, Cambridge CardioMatrix's Active Epicardial Support Device (ASD) is designed to support the heart from its outer surface. The platform combines soft robotic cardiac assistance with continuous physiological monitoring, offering the potential for safer mechanical support while enabling more personalised treatment strategies. Its innovative design also creates opportunities for future therapy optimisation and targeted local delivery of drugs or biologics.

The presentation highlighted Cambridge CardioMatrix's vision of developing a next-generation epicardial support platform that not only assists the failing heart but also provides real-time physiological insights to support precision cardiovascular medicine. The company's integrated approach aims to improve patient outcomes while addressing some of the key limitations of existing heart failure therapies.

Following the presentation, Marshal engaged with investors, entrepreneurs, pharmaceutical companies, and industry representatives during the networking sessions. The event provided valuable opportunities to discuss the commercial potential of the technology, explore future collaborations, and establish new relationships within the UK life sciences and investment community.

"ON Helix brings together an outstanding community of innovators, investors, and industry leaders who are driving the future of life sciences," said Marshal Ma, CEO of Cambridge CardioMatrix. "We were delighted to present our technology and share our vision for transforming the treatment of advanced heart failure through a next-generation epicardial support platform. The discussions throughout the event reinforced the growing interest in innovative cardiovascular technologies that combine therapeutic support with real-time physiological monitoring."

Participation in the ON Helix Pitching Day marks another important step in Cambridge CardioMatrix's engagement with the UK's life sciences ecosystem. The company looks forward to building on the relationships established during the event as it continues to advance its technology towards clinical translation and commercialisation.

Contact

Reach out for support or enquiries

Email:

Phone: +44 1223 981791

info@cardio-matrix.com

© 2025. Cambridge CardioMatrix, All rights reserved.

Find us at the heart of Cambridge, where innovation meets care in every beat

Cambridge CardioMatrix - MedTech International, Allia FBC, Kings Hedges Road, CB4 2HY Cambridge, UK

HOME ABOUT TECHNOLOGY DEVELOPMENT NEWS CONTACT US